SRZN fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
SRZN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company